A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
Ritu Salani, Mary McCormack, Yong-Man Kim, Sharad Ghamande, Shaundra L Hall, Domenica Lorusso, Lisa Barraclough, Lucy Gilbert, Adrian Guzman Ramirez, Chien-Hsing Lu, Renaud Sabatier, Nicoletta Colombo, Youyou Hu, Venkatesh Krishnan, Luciana Molinero, Yuning Feng, Nicole Kim, Marcela Castro, Yvonne G Lin, Bradley J Monk
International Journal of Gynecologic Cancer Aug 2024, 34 (8) 1140-1148; DOI: 10.1136/ijgc-2024-005588
